Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report
Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-06-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/dr/article/view/10324 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218821186486272 |
|---|---|
| author | Carlotta Bertolina Marinella Bertolotti Claudia Leporati Antonina Maria De Angelis Sara Delfanti Luigi Cerbone Marco Ghiglione Federica Grosso |
| author_facet | Carlotta Bertolina Marinella Bertolotti Claudia Leporati Antonina Maria De Angelis Sara Delfanti Luigi Cerbone Marco Ghiglione Federica Grosso |
| author_sort | Carlotta Bertolina |
| collection | DOAJ |
| description |
Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.
|
| format | Article |
| id | doaj-art-4e4b2db8bf4e49d8990136c9ab96aa25 |
| institution | OA Journals |
| issn | 2036-7392 2036-7406 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj-art-4e4b2db8bf4e49d8990136c9ab96aa252025-08-20T02:07:35ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062025-06-0110.4081/dr.2025.10324Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case reportCarlotta Bertolina0https://orcid.org/0000-0001-5458-6914Marinella Bertolotti1https://orcid.org/0000-0003-2152-4930Claudia Leporati2https://orcid.org/0000-0003-1836-6070Antonina Maria De Angelis3Sara Delfanti4https://orcid.org/0000-0002-9862-7340Luigi Cerbone5Marco Ghiglione6Federica Grosso7https://orcid.org/0000-0002-6843-3369Research Training Innovation Infrastructure, Research and Innovation Department, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaResearch Training Innovation Infrastructure, Research and Innovation Department, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaDermatology Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaMesothelioma, Melanoma and Rare Cancers Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaMesothelioma, Melanoma and Rare Cancers Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaMesothelioma, Melanoma and Rare Cancers Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaPlastic and Reconstructive Surgery, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, AlessandriaMesothelioma, Melanoma and Rare Cancers Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes. https://www.pagepress.org/journals/dr/article/view/10324Melanomatargeted therapyimmune checkpoint inhibitorsadverse eventscomplete response |
| spellingShingle | Carlotta Bertolina Marinella Bertolotti Claudia Leporati Antonina Maria De Angelis Sara Delfanti Luigi Cerbone Marco Ghiglione Federica Grosso Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report Dermatology Reports Melanoma targeted therapy immune checkpoint inhibitors adverse events complete response |
| title | Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report |
| title_full | Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report |
| title_fullStr | Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report |
| title_full_unstemmed | Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report |
| title_short | Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report |
| title_sort | durable complete response in a patient with braf mutated advanced melanoma with ocular and skin toxicities from braf mek targeted therapy after immune checkpoint inhibitor treatment a case report |
| topic | Melanoma targeted therapy immune checkpoint inhibitors adverse events complete response |
| url | https://www.pagepress.org/journals/dr/article/view/10324 |
| work_keys_str_mv | AT carlottabertolina durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT marinellabertolotti durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT claudialeporati durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT antoninamariadeangelis durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT saradelfanti durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT luigicerbone durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT marcoghiglione durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport AT federicagrosso durablecompleteresponseinapatientwithbrafmutatedadvancedmelanomawithocularandskintoxicitiesfrombrafmektargetedtherapyafterimmunecheckpointinhibitortreatmentacasereport |